The Maple Grove City Council this week approved plans for a 71,000 square-foot, two-story med-tech facility that will face Interstate Highway 494. ProMed Molded Products, Inc. plans to build the facility on vacant land at Wedgwood Road and 67th Avenue.
ProMed was founded in 1989 and is headquarted in Plymouth. The company makes silicone molded products for medical uses and drug-eluting implantable devices.
According to Brett Angell, economic development manager with Maple Grove, the development would create 185 new jobs within three years of constructing the new facility. Sixty of those employees would not be ProMed workers, but rather employees of other companies that lease from the ProMed facility, said Angell.
The new jobs would average an annual wage of $57,600, which does not include benefits. Ten percent of the jobs would be in the $115,000 to $200,000 range, said Wayne Kelly, CEO and president at ProMed.
ProMed won’t take workers from Plymouth, officials said.
Read the full article on CCX Media
MAA COVID-19 INFORMATION DISCLAIMER:
The Medical Alley Association is providing COVID-19 related information, including the “COVID-19 Resource Connect” feature on its website and summaries of laws, executive orders, and government programs that may be of interest to members, as a public service. The Medical Alley Association makes no representations, guarantees, or warranties as to the accuracy, completeness, currency, or suitability of the COVID-19 related information provided by the Medical Alley Association on its website, in newsletters, or in any other communications. The Medical Alley Association specifically disclaims any and all liability for any claims or damages that may result from providing COVID-19 related information online or in other communications or linking to third party websites or other sources of information. The Medical Alley Association makes no effort to independently verify, and does not exert editorial control over, information provided by third parties.
The Medical Alley Association does not endorse any of the products, vendors, consultants, or documentation referenced in, or connected to parties through, the COVID-19 Resource Connect feature or via email or other communications.
